Patents Assigned to Yamanouchi Pharmaceutical Co., Ltd.
  • Remedies for endothelin-induced diseases
    Patent number: 6774131
    Abstract: A pharmaceutical composition for therapeutically treating prostate cancer, the pharmaceutical composition containing N-[6-methoxy-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyri midinyl]-2-phenylethenesulfoneamide or a pharmaceutically acceptable salt thereof as the effective component.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: August 10, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Hironori Yuyama, Akira Fujimori, Masanao Sanagi, Hironori Harada, Akiko Koakutsu, Mikiko Mori, Nobuyuki Yamamoto
  • Fused heteroaryl derivatives
    Patent number: 6770641
    Abstract: The present invention provides a pharmaceutical composition which is useful as a phosphatidylinositol 3 kinase (PI3K) inhibitor and an antitumor agent, and it provides a novel bicyclic or tricyclic fused heteroaryl derivative or a salt thereof which possesses an excellent PI3K inhibiting activity and cancer cell growth inhibiting activity.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: August 3, 2004
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Ludwig Institute for Cancer Research, Imperial Cancer Research Technology Ltd.
    Inventors: Masahiko Hayakawa, Hiroyuki Kaizawa, Hiroyuki Moritomo, Ken-Ichi Kawaguchi, Tomonobu Koizumi, Mayumi Yamano, Koyo Matsuda, Minoru Okada, Mitsuaki Ohta
  • Novel metalloprotease having aggrecanase activity
    Publication number: 20040142445
    Abstract: This invention provides a novel metalloprotease having an aggrecanase activity which causes joint diseases, a gene coding for this metalloprotease, a promoter of the above metalloprotease, a method for screening a drug with the use of the above metalloprotease and a pharmaceutical composition for inhibiting degradation of proteoglycans, which comprises as the active ingredient a substance capable of inhibiting the aggrecanase activity of the above metalloprotease.
    Type: Application
    Filed: January 26, 2004
    Publication date: July 22, 2004
    Applicants: YAMANOUCHI PHARMACEUTICAL CO., LTD., KAZUSA DNA RESEARCH INSTITUTE
    Inventors: Noboru Yamaji, Kouichi Nishimura, Kunitake Abe, Osamu Ohara, Takahiro Nagase, Nobuo Nomura
  • Drug delivery system for averting pharmacokinetic drug interaction and method thereof
    Patent number: 6761895
    Abstract: The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: July 13, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
  • Naphthyridine derivatives
    Patent number: 6740662
    Abstract: 2-Oxo-1,2-dihydro-1,8-naphthyridine derivatives characterized by bearing a specific substituent, —X—R6, at the 3-position and a cyclic substituent, R5, at the 4-position; or salts thereof. The derivatives and the salts are useful as drugs, particularly preventive or therapeutic agents for respiratory diseases related to PDE IV.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: May 25, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masahiro Iwata, Noriyuki Kawano, Tomofumi Takuwa, Ryota Shiraki, Miki Kobayashi, Makoto Takeuchi
  • Soluble drug extended release system
    Publication number: 20040091528
    Abstract: This invention relates to novel oral sustained-release formulations for delivery of an active agent (e.g., a drug), especially a highly water soluble drug. More particularly, this invention relates to novel formulations comprising a micelle-forming drug having a charge and at least one polymer having an opposite charge. Methods of using the novel formulations are also provided.
    Type: Application
    Filed: November 12, 2002
    Publication date: May 13, 2004
    Applicants: Yamanouchi Pharma Technologies, Inc., Yamanouchi Pharmaceutical Co. Ltd.
    Inventors: Victoria Rogers, Philippe J.M. Dor, Joseph A. Fix, Hiroyuki Kojima, Kazuhiro Sako
  • Pharmaceuticals for neuropathic pain
    Publication number: 20040087608
    Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.
    Type: Application
    Filed: June 26, 2003
    Publication date: May 6, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe
  • Novel depsipeptide compound
    Publication number: 20040082054
    Abstract: This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.
    Type: Application
    Filed: October 15, 2003
    Publication date: April 29, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Koji Nagai, Nakako Arao, Kinya Souda, Kazuma Kamigiri, Masamichi Mori, Nobuaki Shindo, Haruo Seto, Kazuo Shin-Ya
  • Medicinal compositions for treating osseous lesion in multiple myeloma
    Patent number: 6727233
    Abstract: Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid or its salt.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: April 27, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Shohei Tanaka, Utane Matsukawa, Hironobu Asano
  • Quick disintegrating tablet in buccal cavity and manufacturing method thereof
    Publication number: 20040071773
    Abstract: The present invention pertains to a quick disintegrating tablet in buccal cavity, characterized in that drug-containing particles with a mean particle diameter of approximately 50˜approximately 250 &mgr;m and an apparent specific gravity of approximately 0.5˜approximately 1.2 consisting of a bitter tasting drug and/or drug of inferior fluidity and a pharmaceutical preparation carrier and obtained by spray drying are added to a quick disintegrating tablet in buccal cavity comprising a drug and saccharide.
    Type: Application
    Filed: September 18, 2003
    Publication date: April 15, 2004
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Atushi Kajiyama, Tetsuya Tamura, Takao Mizumoto, Hitoshi Kawai, Tatsuya Takahashi
  • Diazepan derivatives or salts thereof
    Publication number: 20040068109
    Abstract: To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan derivative such as 4-[(3-carbamimidoylphenylamino)methyl]-3-[4-(4-methyl-1,4-diazepan-1-yl)benzoylamino]benzoic acid and 3-hydroxy-4′-methoxy-2-{[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]amino}benzanilide or a salt thereof is an effective ingredient.
    Type: Application
    Filed: September 8, 2003
    Publication date: April 8, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO. LTD.
    Inventors: Fukushi Hirayama, Hiroyuki Koshio, Tsukasa Ishihara, Norio Seki, Shunichiro Hachiya, Keizo Sugasawa, Ryota Shiraki, Yuji Koga, Yuzo Matsumoto, Takeshi Shigenaga, Souichirou Kawazoe
  • Metalloprotease having aggrecanase activity
    Patent number: 6716613
    Abstract: This invention provides a novel metalloprotease having an aggrecanase activity which causes joint diseases, a gene coding for this metalloprotease, a promoter of the above metalloprotease, a method for screening a drug with the use of the above metalloprotease and a pharmaceutical composition for inhibiting degradation of proteoglycans, which comprises as the active ingredient a substance capable of inhibiting the aggrecanase activity of the above metalloprotease.
    Type: Grant
    Filed: December 10, 2001
    Date of Patent: April 6, 2004
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Kazusa DNA Research Institute
    Inventors: Noboru Yamaji, Kouichi Nishimura, Kunitake Abe, Osamu Ohara, Takahiro Nagase, Nobuo Nomura
  • Bitterness-reduced oral pharmaceutical composition
    Patent number: 6706284
    Abstract: The invention relates to an oral pharmaceutical composition which has excellent drug release-controlling ability in the mouth even 5 to 10 minutes after its administration and also has excellent drug releasing ability in the digestive tract without using capsules. It also relates to an oral pharmaceutical composition which comprises one or more drugs having a bitter taste, one or more solid proteins, and one or more pharmaceutically acceptable polymer bases, wherein the proteins are present in the polymer bases preferably as particles.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: March 16, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masahiro Yanagisawa, Takao Mizumoto
  • Pharmaceutical compositions for treating bone lesions in multiple myeloma
    Publication number: 20040043966
    Abstract: Pharmaceutical compositions for treating bone lesions in multiple myeloma or pharmaceutical compositions for treating multiple myeloma which contain as an active ingredient a compound having both of an effect of suppressing bone resorption accompanying multiple myeloma and an effect of inhibiting multiple myeloma, more particularly, 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-l,l-bisphosphonic acid or its salt.
    Type: Application
    Filed: September 2, 2003
    Publication date: March 4, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Shohei Tanaka, Utane Matsukawa, Hironobu Sano
  • Remedies for periodontosis
    Patent number: 6682718
    Abstract: The invention relates to an alveolar bone resorption inhibitor for use in topical injection by an alveolar mucosa injection method, which comprises a bisphosphonic acid derivative or a salt thereof as an active ingredient and to an alveolar bone resorption inhibitor for human periodontal tissue topical injection, which comprises a bisphosphonic acid derivative or a salt thereof in a concentration small enough so that local irritation to human periodontal tissues as the administrating site is acceptable but sufficient enough for expressing alveolar bone resorption inhibitory action by topical injection.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: January 27, 2004
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Naoto O'Uchi, Takaya Iwai, Taiji Yoshino, Hiroyuki Kanoh, Hiroyuki Motoie
  • Cyanophenyl derivative
    Publication number: 20040010037
    Abstract: This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.
    Type: Application
    Filed: June 30, 2003
    Publication date: January 15, 2004
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Nobuaki Taniguchi, Isao Kinoyama, Takashi Kamikubo, Akira Toyoshima, Kiyohiro Samizu, Eiji Kawaminami, Masakazu Imamura, Hiroyuki Moritomo, Akira Matsuhisa, Masaaki Hirano, Yoji Miyazaki, Eisuke Nozawa, Minoru Okada, Hiroshi Koutoku, Mitsuaki Ohta
  • Cyanophenyl derivative
    Patent number: 6673799
    Abstract: This application relates to a piperazino-substituted novel cyanophenyl derivative in which a substituted carbamoyl or substituted sulfamoyl group having an aryl, heterocyclic or the like group that may have a substituent group is bonded to one nitrogen atom on the piperazine ring. The compound of this application has an anti-androgen action and is useful in preventing or treating prostatic cancer, benign prostatic hyperplasia and the like diseases.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: January 6, 2004
    Assignee: Yamanouchi Pharmaceutical Co. Ltd.
    Inventors: Nobuaki Taniguchi, Isao Kinoyama, Takashi Kamikubo, Akira Toyoshima, Kiyohiro Samizu, Eiji Kawaminami, Masakazu Imamura, Hiroyuki Moritomo, Akira Matsuhisa, Masaaki Hirano, Yoji Miyazaki, Eisuke Nozawa, Minoru Okada, Hiroshi Koutoku, Mitsuaki Ohta
  • Depsipeptide compound
    Patent number: 6670326
    Abstract: This invention relates to a novel compound which has a cytotoxic activity and TGF-&bgr; like activity for human cancer cells and is useful as an antitumor agent and to a pharmaceutical composition which contains the same.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: December 30, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Koji Nagai, Nakako Arao, Kinya Souda, Kazuma Kamigiri, Masamichi Mori, Nobuaki Shindo, Haruo Seto, Kazuo Shin-Ya
  • Pharmaceuticals for neurogenic pain
    Patent number: 6664283
    Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: December 16, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe
  • Quick disintegrating tablet in buccal cavity and manufacturing method thereof
    Patent number: 6656492
    Abstract: The present invention pertains to a quick disintegrating tablet in buccal cavity, characterized in that drug-containing particles with a mean particle diameter of approximately 50˜approximately 250 &mgr;m and an apparent specific gravity of approximately 0.5˜approximately 1.2 consisting of a bitter tasting drug and/or drug of inferior fluidity and a pharmaceutical preparation carrier and obtained by spray drying are added to a quick disintegrating tablet in buccal cavity comprising a drug and saccharide.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: December 2, 2003
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Atushi Kajiyama, Tetsuya Tamura, Takao Mizumoto, Hitoshi Kawai, Tatsuya Takahashi